TIMOTHY LEE SCHOONOVER
- Type
- Physician · Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology
- Where
- CENTERVILLE, OH
- NPI
- 1033111802
- Received
- $392,021 in 1,514 records, 2019 to 2025 ($386,769 general, $5,252 research); ownership interests with $55,003 invested
- As principal investigator
- $224,182 of research payments to others in 111 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 189 | $40,068 |
| 2024 | General payment | 170 | $20,550 |
| 2023 | General payment | 164 | $26,694 |
| 2022 | General payment | 242 | $60,703 |
| 2022 | Research payment | 1 | $258 |
| 2021 | General payment | 264 | $92,319 |
| 2021 | Research payment | 1 | $4,994 |
| 2020 | General payment | 162 | $44,687 |
| 2019 | General payment | 320 | $101,745 |
| 2019 | Ownership or investment interest | 1 | $55,003 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 161 | $337,719 |
| Ownership or investment interest | 1 | $55,003 |
| Food and Beverage | 1,290 | $29,312 |
| Travel and Lodging | 54 | $19,341 |
| Research payment | 2 | $5,252 |
| Consulting Fee | 1 | $250 |
| Education | 5 | $146 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-22 | Neurelis, Inc. | $18 | Food and Beverage | In-kind items and services | VALTOCO Drug, EPILEPSY | 2025 | |
| 2025-12-19 | GENZYME CORPORATION | $29 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-12-17 | PFIZER INC. | $18 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-12-17 | ABBVIE INC. | $1 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-12-17 | ABBVIE INC. | $1 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-12-15 | Amneal Pharmaceuticals LLC | $28 | Food and Beverage | In-kind items and services | CREXONT Drug, NEUROLOGY | 2025 | |
| 2025-12-10 | PFIZER INC. | $17 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-12-08 | Neurocrine BioSciences, Inc. | $18 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-12-08 | Neurocrine BioSciences, Inc. | $1 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-12-05 | ABBVIE INC. | $24 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2025 | |
| 2025-12-05 | Neurocrine BioSciences, Inc. | $13 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-12-04 | ABBVIE INC. | $3,675 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | UBRELVY Drug, NEUROSCIENCE | 2025 | |
| 2025-12-04 | SK Life Science, Inc. | $32 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-11-20 | MDD US Operations, LLC | $21 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-11-20 | Novartis Pharmaceuticals Corporation | $15 | Food and Beverage | In-kind items and services | KESIMPTA Drug, Neurology | 2025 | |
| 2025-11-19 | ABBVIE INC. | $1,238 | Travel and Lodging | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2025 | |
| 2025-11-19 | ABBVIE INC. | $101 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-11-19 | ABBVIE INC. | $18 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-11-19 | Teva Pharmaceuticals USA, Inc. | $18 | Food and Beverage | In-kind items and services | AUSTEDO XR Drug, Central Nervous System | 2025 | |
| 2025-11-17 | ABBVIE INC. | $16 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-11-16 | Eisai Inc. | $16 | Food and Beverage | In-kind items and services | Leqembi Drug, Neurology | 2025 | |
| 2025-11-12 | Merz Pharmaceuticals, LLC | $19 | Food and Beverage | In-kind items and services | Xeomin Biological, Musculoskeletal | 2025 | |
| 2025-11-07 | Novartis Pharmaceuticals Corporation | $17 | Food and Beverage | In-kind items and services | KESIMPTA Drug, Neurology | 2025 | |
| 2025-11-06 | EMD Serono, Inc. | $25 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-11-06 | Neurocrine BioSciences, Inc. | $23 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-11-05 | Amneal Pharmaceuticals LLC | $12 | Food and Beverage | In-kind items and services | BREKIYA Drug, NEUROLOGY | 2025 | |
| 2025-11-04 | Amneal Pharmaceuticals LLC | $25 | Food and Beverage | In-kind items and services | CREXONT Drug, NEUROLOGY | 2025 | |
| 2025-11-03 | ACADIA Pharmaceuticals Inc | $24 | Food and Beverage | In-kind items and services | NUPLAZID Drug, PARKINSONS DISEASE PSYCHOSIS | 2025 | |
| 2025-10-31 | SpringWorks Therapeutics, Inc. | $15 | Food and Beverage | In-kind items and services | GOMEKLI Drug, NEUROFIBROMATOSIS TYPE 1-ASSOCIATED PLEXIFORM NEUROFIBROMAS | 2025 | |
| 2025-10-31 | ABBVIE INC. | $8 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-10-30 | UCB, Inc. | $21 | Food and Beverage | In-kind items and services | Nayzilam Drug, Neurology | 2025 | |
| 2025-10-30 | ABBVIE INC. | $6 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-10-29 | ABBVIE INC. | $787 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BOTOX Biological, NEUROSCIENCE | 2025 | |
| 2025-10-29 | Lilly USA, LLC | $27 | Food and Beverage | In-kind items and services | AMYVID Drug, Neuroscience | 2025 | |
| 2025-10-29 | Eisai Inc. | $17 | Food and Beverage | In-kind items and services | Leqembi Drug, Neurology | 2025 | |
| 2025-10-24 | Alexion Pharmaceuticals, Inc. | $35 | Food and Beverage | In-kind items and services | ULTOMIRIS Biological, Rare Disease | 2025 | |
| 2025-10-22 | ABBVIE INC. | $26 | Food and Beverage | In-kind items and services | VYALEV Drug, NEUROSCIENCE | 2025 | |
| 2025-10-22 | REVANCE THERAPEUTICS, INC. | $22 | Food and Beverage | In-kind items and services | DAXXIFY Drug, AESTHETICS AND THERAPEUTICS | 2025 | |
| 2025-10-22 | UCB, Inc. | $15 | Food and Beverage | In-kind items and services | Zilbrysq Drug, Neurology | 2025 | |
| 2025-10-22 | UCB, Inc. | $2 | Food and Beverage | In-kind items and services | Zilbrysq Drug, Neurology | 2025 | |
| 2025-10-16 | PFIZER INC. | $15 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-10-15 | SK Life Science, Inc. | $16 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-08 | Eisai Inc. | $14 | Food and Beverage | In-kind items and services | Leqembi Drug, Neurology | 2025 | |
| 2025-10-06 | HARMONY BIOSCIENCES LLC | $29 | Food and Beverage | In-kind items and services | WAKIX Drug, NARCOLEPSY | 2025 | |
| 2025-09-17 | ARGENX US, INC. | $26 | Food and Beverage | In-kind items and services | VYVGART Drug, Immunology | 2025 | |
| 2025-09-17 | Teva Pharmaceuticals USA, Inc. | $19 | Food and Beverage | In-kind items and services | AUSTEDO XR Drug, Central Nervous System | 2025 | |
| 2025-09-16 | ABBVIE INC. | $22 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-09-15 | Biogen, Inc. | $14 | Food and Beverage | In-kind items and services | VUMERITY Drug, Neurology | 2025 | |
| 2025-09-12 | Neurocrine BioSciences, Inc. | $14 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-09-10 | ABBVIE INC. | $21 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2025 | |
| 2025-09-10 | ABBVIE INC. | $5 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-09-09 | ABBVIE INC. | $33 | Food and Beverage | In-kind items and services | VYALEV Drug, NEUROSCIENCE | 2025 | |
| 2025-09-08 | Lilly USA, LLC | $18 | Food and Beverage | In-kind items and services | AMYVID Drug, Neuroscience | 2025 | |
| 2025-09-05 | ABBVIE INC. | $10 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-09-03 | PFIZER INC. | $12 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-09-02 | ABBVIE INC. | $5 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-08-27 | JAZZ PHARMACEUTICALS INC. | $24 | Food and Beverage | In-kind items and services | XYWAV Drug, NEUROLOGY | 2025 | |
| 2025-08-27 | Amneal Pharmaceuticals LLC | $22 | Food and Beverage | In-kind items and services | CREXONT Drug, NEUROLOGY | 2025 | |
| 2025-08-25 | PFIZER INC. | $17 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-08-21 | ABBVIE INC. | $3,675 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-08-21 | ABBVIE INC. | $886 | Travel and Lodging | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-08-21 | ABBVIE INC. | $119 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-08-20 | UCB, Inc. | $28 | Food and Beverage | In-kind items and services | Fintepla Drug, Neurology | 2025 | |
| 2025-08-20 | Eisai Inc. | $22 | Food and Beverage | In-kind items and services | Leqembi Drug, Neurology | 2025 | |
| 2025-08-19 | Teva Pharmaceuticals USA, Inc. | $18 | Food and Beverage | In-kind items and services | AUSTEDO XR Drug, Central Nervous System | 2025 | |
| 2025-08-18 | Eisai Inc. | $24 | Food and Beverage | In-kind items and services | Leqembi Drug, Neurology | 2025 | |
| 2025-08-13 | Takeda Pharmaceuticals U.S.A., Inc. | $19 | Food and Beverage | In-kind items and services | HYQVIA Biological, IMMUNOLOGY | 2025 | |
| 2025-08-13 | Genentech USA, Inc. | $15 | Food and Beverage | In-kind items and services | Ocrevus Biological, Immunology | 2025 | |
| 2025-08-01 | Biogen, Inc. | $23 | Food and Beverage | In-kind items and services | SKYCLARYS Drug, Neurology | 2025 | |
| 2025-07-31 | Novartis Pharmaceuticals Corporation | $17 | Food and Beverage | In-kind items and services | KESIMPTA Drug, Neurology | 2025 | |
| 2025-07-30 | ABBVIE INC. | $20 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2025 | |
| 2025-07-30 | ABBVIE INC. | $15 | Food and Beverage | In-kind items and services | VYALEV Drug, NEUROSCIENCE | 2025 | |
| 2025-07-29 | ABBVIE INC. | $21 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-07-28 | Neurocrine BioSciences, Inc. | $22 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-07-28 | Neurocrine BioSciences, Inc. | $2 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-07-23 | InSightec,Inc | $16 | Food and Beverage | Cash or cash equivalent | Exablate Device, Neurology | 2025 | |
| 2025-07-16 | UCB, Inc. | $89 | Food and Beverage | In-kind items and services | Rystiggo Drug, Neurology | 2025 | |
| 2025-07-16 | Amneal Pharmaceuticals LLC | $22 | Food and Beverage | In-kind items and services | CREXONT Drug, NEUROLOGY | 2025 | |
| 2025-07-16 | ABBVIE INC. | $14 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-07-09 | Biogen, Inc. | $15 | Food and Beverage | In-kind items and services | TYSABRI Biological, Neurology | 2025 | |
| 2025-07-02 | ABBVIE INC. | $2,625 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BOTOX Biological, NEUROSCIENCE | 2025 | |
| 2025-07-02 | ABBVIE INC. | $86 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2025 | |
| 2025-07-02 | ABBVIE INC. | $23 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2025 | |
| 2025-07-02 | PFIZER INC. | $18 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-07-01 | ABBVIE INC. | $16 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-06-26 | Lilly USA, LLC | $16 | Food and Beverage | In-kind items and services | AMYVID Drug, Neuroscience | 2025 | |
| 2025-06-25 | ABBVIE INC. | $15 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2025 | |
| 2025-06-25 | PFIZER INC. | $10 | Food and Beverage | In-kind items and services | PANZYGA Biological, IMMUNOLOGY;INFLAMMATION | 2025 | |
| 2025-06-24 | ABBVIE INC. | $78 | Food and Beverage | In-kind items and services | BOTOX Biological, NEUROSCIENCE | 2025 | |
| 2025-06-24 | ACADIA Pharmaceuticals Inc | $24 | Food and Beverage | In-kind items and services | NUPLAZID Drug, PARKINSONS DISEASE PSYCHOSIS | 2025 | |
| 2025-06-24 | PFIZER INC. | $22 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-06-23 | ABBVIE INC. | $3,675 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-06-23 | ABBVIE INC. | $2,625 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-06-21 | PFIZER INC. | $15 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-06-18 | Ipsen Biopharmaceuticals, Inc | $16 | Food and Beverage | In-kind items and services | Dysport Drug, Neurology | 2025 | |
| 2025-06-18 | Teva Pharmaceuticals USA, Inc. | $15 | Food and Beverage | In-kind items and services | AUSTEDO XR Drug, Central Nervous System | 2025 | |
| 2025-06-18 | Teva Pharmaceuticals USA, Inc. | $1 | Food and Beverage | In-kind items and services | AUSTEDO XR Drug, Central Nervous System | 2025 | |
| 2025-06-17 | Genentech USA, Inc. | $22 | Food and Beverage | In-kind items and services | Ocrevus Biological, Immunology | 2025 | |
| 2025-06-16 | ARGENX US, INC. | $26 | Food and Beverage | In-kind items and services | VYVGART Drug, Immunology | 2025 | |
| 2025-06-14 | ABBVIE INC. | $26 | Food and Beverage | In-kind items and services | VYALEV Drug, NEUROSCIENCE | 2025 | |
| 2025-06-12 | ABBVIE INC. | $866 | Travel and Lodging | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-06-12 | ABBVIE INC. | $125 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2025 | |
| 2025-06-11 | ABBVIE INC. | $125 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-06-11 | Alexion Pharmaceuticals, Inc. | $22 | Food and Beverage | In-kind items and services | ULTOMIRIS Biological, Rare Disease | 2025 | |
| 2025-06-10 | ABBVIE INC. | $787 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BOTOX Biological, NEUROSCIENCE | 2025 | |
| 2025-06-09 | ABBVIE INC. | $17 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-06-04 | MDD US Operations, LLC | $17 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-06-04 | ABBVIE INC. | $13 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-06-03 | Lundbeck LLC | $24 | Food and Beverage | Cash or cash equivalent | VYEPTI Biological, NEUROLOGY | 2025 | |
| 2025-06-02 | ABBVIE INC. | $11 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-05-28 | ABBVIE INC. | $4,200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BOTOX Biological, NEUROSCIENCE | 2025 | |
| 2025-05-14 | Lilly USA, LLC | $17 | Food and Beverage | In-kind items and services | AMYVID Drug, Neuroscience | 2025 | |
| 2025-05-13 | ABBVIE INC. | $11 | Food and Beverage | In-kind items and services | VYALEV Drug, NEUROSCIENCE | 2025 | |
| 2025-05-12 | ABBVIE INC. | $525 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BOTOX Biological, NEUROSCIENCE | 2025 | |
| 2025-05-12 | ABBVIE INC. | $17 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2025 | |
| 2025-05-12 | MDD US Operations, LLC | $16 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-05-07 | Amneal Pharmaceuticals LLC | $20 | Food and Beverage | In-kind items and services | CREXONT Drug, NEUROLOGY | 2025 | |
| 2025-05-03 | ABBVIE INC. | $19 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-05-02 | ABBVIE INC. | $6 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-05-01 | ABBVIE INC. | $20 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2025 | |
| 2025-04-30 | AstraZeneca Pharmaceuticals LP | $15 | Food and Beverage | In-kind items and services | WAINUA Drug, Cardiovascular and Metabolism | 2025 | |
| 2025-04-29 | ABBVIE INC. | $2,756 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BOTOX Biological, NEUROSCIENCE | 2025 | |
| 2025-04-24 | Alexion Pharmaceuticals, Inc. | $22 | Food and Beverage | In-kind items and services | ULTOMIRIS Biological, Rare Disease | 2025 | |
| 2025-04-23 | SK Life Science, Inc. | $14 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-04-22 | Genentech USA, Inc. | $20 | Food and Beverage | In-kind items and services | Ocrevus Zunovo Biological, Immunology | 2025 | |
| 2025-04-21 | ABBVIE INC. | $19 | Food and Beverage | In-kind items and services | VYALEV Drug, NEUROSCIENCE | 2025 | |
| 2025-04-16 | Eisai Inc. | $29 | Food and Beverage | In-kind items and services | Leqembi Drug, Neurology | 2025 | |
| 2025-04-12 | Biogen, Inc. | $22 | Food and Beverage | In-kind items and services | VUMERITY Drug, Neurology | 2025 | |
| 2025-04-10 | Lundbeck LLC | $17 | Food and Beverage | Cash or cash equivalent | VYEPTI Biological, NEUROLOGY | 2025 | |
| 2025-04-09 | ABBVIE INC. | $18 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-04-08 | Teva Pharmaceuticals USA, Inc. | $19 | Food and Beverage | In-kind items and services | AUSTEDO XR Drug, Central Nervous System | 2025 | |
| 2025-04-08 | Teva Pharmaceuticals USA, Inc. | $1 | Food and Beverage | In-kind items and services | AUSTEDO XR Drug, Central Nervous System | 2025 | |
| 2025-04-07 | ABBVIE INC. | $4,200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BOTOX Biological, NEUROSCIENCE | 2025 | |
| 2025-04-07 | ABBVIE INC. | $18 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2025 | |
| 2025-04-04 | Neurocrine BioSciences, Inc. | $28 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-04-04 | Eisai Inc. | $24 | Food and Beverage | In-kind items and services | Leqembi Drug, Neurology | 2025 | |
| 2025-04-01 | ACADIA Pharmaceuticals Inc | $29 | Food and Beverage | In-kind items and services | NUPLAZID Drug, PARKINSONS DISEASE PSYCHOSIS | 2025 | |
| 2025-03-31 | PFIZER INC. | $16 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-03-29 | ABBVIE INC. | $525 | Travel and Lodging | In-kind items and services | BOTOX Biological, NEUROSCIENCE | 2025 | |
| 2025-03-29 | ABBVIE INC. | $326 | Travel and Lodging | In-kind items and services | BOTOX Biological, NEUROSCIENCE | 2025 | |
| 2025-03-29 | ABBVIE INC. | $69 | Food and Beverage | In-kind items and services | BOTOX Biological, NEUROSCIENCE | 2025 | |
| 2025-03-29 | ABBVIE INC. | $59 | Food and Beverage | In-kind items and services | BOTOX Biological, NEUROSCIENCE | 2025 | |
| 2025-03-29 | ABBVIE INC. | $24 | Food and Beverage | In-kind items and services | BOTOX Biological, NEUROSCIENCE | 2025 | |
| 2025-03-28 | ABBVIE INC. | $124 | Food and Beverage | In-kind items and services | BOTOX Biological, NEUROSCIENCE | 2025 | |
| 2025-03-26 | ABBVIE INC. | $24 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2025 | |
| 2025-03-26 | Merz Pharmaceuticals, LLC | $22 | Food and Beverage | In-kind items and services | Xeomin Biological, Musculoskeletal | 2025 | |
| 2025-03-25 | ABBVIE INC. | $17 | Food and Beverage | In-kind items and services | VYALEV Drug, NEUROSCIENCE | 2025 | |
| 2025-03-24 | Takeda Pharmaceuticals U.S.A., Inc. | $22 | Food and Beverage | In-kind items and services | HYQVIA Biological, IMMUNOLOGY | 2025 | |
| 2025-03-21 | Amneal Pharmaceuticals LLC | $20 | Food and Beverage | In-kind items and services | CREXONT Drug, NEUROLOGY | 2025 | |
| 2025-03-20 | Teva Pharmaceuticals USA, Inc. | $15 | Food and Beverage | In-kind items and services | AUSTEDO XR Drug, Central Nervous System | 2025 | |
| 2025-03-17 | ABBVIE INC. | $21 | Food and Beverage | In-kind items and services | VYALEV Drug, NEUROSCIENCE | 2025 | |
| 2025-03-14 | EMD Serono, Inc. | $44 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-03-07 | Novartis Pharmaceuticals Corporation | $15 | Food and Beverage | In-kind items and services | KESIMPTA Drug, Neurology | 2025 | |
| 2025-03-06 | Lilly USA, LLC | $16 | Food and Beverage | In-kind items and services | EMGALITY Drug, Neuroscience | 2025 | |
| 2025-03-05 | MDD US Operations, LLC | $18 | Food and Beverage | In-kind items and services | Gocovri Drug, AMANTADINE | 2025 | |
| 2025-03-04 | Ipsen Biopharmaceuticals, Inc | $14 | Food and Beverage | In-kind items and services | Dysport Drug, Neurology | 2025 | |
| 2025-03-03 | PFIZER INC. | $19 | Food and Beverage | In-kind items and services | PANZYGA Biological, IMMUNOLOGY;INFLAMMATION | 2025 | |
| 2025-02-28 | Eisai Inc. | $15 | Food and Beverage | In-kind items and services | Leqembi Drug, Neurology | 2025 | |
| 2025-02-26 | SK Life Science, Inc. | $26 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-02-26 | UCB, Inc. | $16 | Food and Beverage | In-kind items and services | Briviact Drug, Neurology | 2025 | |
| 2025-02-24 | Merz Pharmaceuticals, LLC | $14 | Food and Beverage | In-kind items and services | Xeomin Biological, Musculoskeletal | 2025 | |
| 2025-02-21 | Amneal Pharmaceuticals LLC | $24 | Food and Beverage | In-kind items and services | CREXONT Drug, NEUROLOGY | 2025 | |
| 2025-02-20 | PFIZER INC. | $16 | Food and Beverage | In-kind items and services | ZAVZPRET Drug, PAIN | 2025 | |
| 2025-02-19 | EMD Serono, Inc. | $20 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-02-19 | Teva Pharmaceuticals USA, Inc. | $16 | Food and Beverage | In-kind items and services | AUSTEDO XR Drug, Central Nervous System | 2025 | |
| 2025-02-19 | ABBVIE INC. | $12 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-02-19 | Teva Pharmaceuticals USA, Inc. | $1 | Food and Beverage | In-kind items and services | AUSTEDO XR Drug, Central Nervous System | 2025 | |
| 2025-02-18 | Eisai Inc. | $23 | Food and Beverage | In-kind items and services | Leqembi Drug, Neurology | 2025 | |
| 2025-02-14 | PFIZER INC. | $13 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-02-14 | Neurocrine BioSciences, Inc. | $9 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-02-11 | Lundbeck LLC | $18 | Food and Beverage | Cash or cash equivalent | VYEPTI Biological, NEUROLOGY | 2025 | |
| 2025-02-04 | ABBVIE INC. | $2,625 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-01-31 | UCB, Inc. | $19 | Food and Beverage | In-kind items and services | Briviact Drug, Neurology | 2025 | |
| 2025-01-29 | Teva Pharmaceuticals USA, Inc. | $17 | Food and Beverage | In-kind items and services | AUSTEDO XR Drug, Central Nervous System | 2025 | |
| 2025-01-29 | Teva Pharmaceuticals USA, Inc. | $1 | Food and Beverage | In-kind items and services | AUSTEDO XR Drug, Central Nervous System | 2025 | |
| 2025-01-28 | Eisai Inc. | $23 | Food and Beverage | In-kind items and services | Leqembi Drug, Neurology | 2025 | |
| 2025-01-28 | Lundbeck LLC | $17 | Food and Beverage | Cash or cash equivalent | VYEPTI Biological, NEUROLOGY | 2025 | |
| 2025-01-24 | EMD Serono, Inc. | $16 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-01-23 | ABBVIE INC. | $32 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2025 | |
| 2025-01-16 | PFIZER INC. | $14 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-01-16 | ABBVIE INC. | $10 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-01-15 | ABBVIE INC. | $125 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-01-14 | Neurocrine BioSciences, Inc. | $17 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-01-14 | Neurocrine BioSciences, Inc. | $1 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-01-13 | Neurelis, Inc. | $20 | Food and Beverage | In-kind items and services | VALTOCO Drug, EPILEPSY | 2025 | |
| 2025-01-10 | Novartis Pharmaceuticals Corporation | $22 | Food and Beverage | In-kind items and services | KESIMPTA Drug, Neurology | 2025 | |
| 2025-01-09 | SK Life Science, Inc. | $21 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-01-03 | ARGENX US, INC. | $21 | Food and Beverage | In-kind items and services | VYVGART HYTRULO Drug, Neurology | 2025 | |
| 2025-01-02 | Lilly USA, LLC | $18 | Food and Beverage | In-kind items and services | EMGALITY Drug, Neuroscience | 2025 | |
| 2024-12-30 | Grifols USA, LLC | $18 | Food and Beverage | In-kind items and services | Gamunex-C Biological, Immunology and Neurology | 2024 | |
| 2024-12-19 | ABBVIE INC. | $20 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2024 | |
| 2024-12-18 | Novartis Pharmaceuticals Corporation | $21 | Food and Beverage | In-kind items and services | KESIMPTA Drug, Neurology | 2024 | |
| 2024-12-17 | Teva Pharmaceuticals USA, Inc. | $14 | Food and Beverage | In-kind items and services | Austedo XR Drug, Central Nervous System | 2024 | |
| 2024-12-16 | Lundbeck LLC | $26 | Food and Beverage | Cash or cash equivalent | VYEPTI Biological, NEUROLOGY | 2024 | |
| 2024-12-11 | SK Life Science, Inc. | $24 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-12-11 | Eisai Inc. | $23 | Food and Beverage | In-kind items and services | Leqembi Drug, Neurology | 2024 | |
| 2024-12-10 | ABBVIE INC. | $23 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2024 | |
| 2024-12-05 | ABBVIE INC. | $3 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2024 | |
| 2024-12-04 | PFIZER INC. | $16 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2024 | |
| 2024-12-02 | UCB, Inc. | $16 | Food and Beverage | In-kind items and services | Zilbrysq Drug, Neurology | 2024 |
The latest 200 records of 1,514.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-09-24 | Regeneron Pharmaceuticals, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS | $140 | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptoma | 2025 |
| 2025-07-25 | Regeneron Pharmaceuticals, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS | $220 | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptoma | 2025 |
| 2025-07-25 | Regeneron Pharmaceuticals, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS | $800 | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptoma | 2025 |
| 2025-07-10 | Eli Lilly and Company | DAYTON CENTER FOR NEUROLOGICAL DISORDERS | $547 | PREVENTIVE TREATMENT OF MIGRAINE: OUTCOMES FOR PATIENTS IN REAL-WORLD HEALTHCARE SYSTEMS (TRIUMPH) | 2025 |
| 2025-06-20 | Regeneron Pharmaceuticals, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS | $20 | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptoma | 2025 |
| 2025-06-20 | Regeneron Pharmaceuticals, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS | $120 | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptoma | 2025 |
| 2025-06-20 | Regeneron Pharmaceuticals, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS | $20 | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptoma | 2025 |
| 2025-06-20 | Regeneron Pharmaceuticals, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS | $20 | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptoma | 2025 |
| 2025-06-20 | Regeneron Pharmaceuticals, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS | $800 | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptoma | 2025 |
| 2025-05-28 | Regeneron Pharmaceuticals, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS | $131 | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptoma | 2025 |
| 2025-05-28 | Regeneron Pharmaceuticals, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS | $20 | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptoma | 2025 |
| 2025-05-28 | Regeneron Pharmaceuticals, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS | $40 | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptoma | 2025 |
| 2025-04-23 | Regeneron Pharmaceuticals, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS | $620 | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptoma | 2025 |
| 2025-04-23 | Regeneron Pharmaceuticals, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS | $1,347 | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptoma | 2025 |
| 2025-04-23 | Regeneron Pharmaceuticals, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS | $650 | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptoma | 2025 |
| 2025-04-23 | Regeneron Pharmaceuticals, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS | $1,500 | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptoma | 2025 |
| 2025-04-23 | Regeneron Pharmaceuticals, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS | $1,000 | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptoma | 2025 |
| 2025-04-23 | Regeneron Pharmaceuticals, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS | $800 | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptoma | 2025 |
| 2025-04-23 | Regeneron Pharmaceuticals, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS | $650 | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptoma | 2025 |
| 2024-08-13 | Novartis Pharmaceuticals Corporation | DAYTON CENTER FOR NEUROLOGICAL DISORDERS, INC | $6,000 | An Open-label Multicenter Study to Assess Response to COVID-19 Vaccine in Participants With Multiple Sclerosis Treated W | 2024 |
| 2024-01-24 | Regeneron Pharmaceuticals, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS | $750 | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptoma | 2024 |
| 2024-01-24 | Regeneron Pharmaceuticals, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS | $11,450 | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptoma | 2024 |
| 2024-01-24 | Regeneron Pharmaceuticals, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS | $3,000 | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptoma | 2024 |
| 2024-01-24 | Regeneron Pharmaceuticals, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS | $115 | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptoma | 2024 |
| 2024-01-02 | Eli Lilly and Company | DAYTON CENTER FOR NEUROLOGICAL DISORDERS | $1,035 | PREVENTIVE TREATMENT OF MIGRAINE: OUTCOMES FOR PATIENTS IN REAL-WORLD HEALTHCARE SYSTEMS (TRIUMPH) | 2024 |
| 2023-05-18 | Teva Pharmaceuticals USA, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC | $895 | A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i | 2023 |
| 2023-03-22 | Novartis Pharmaceuticals Corporation | DAYTON CENTER FOR NEUROLOGICAL DISORDERS, INC | $15,644 | An Open-label Multicenter Study to Assess Response to COVID-19 Vaccine in Participants With Multiple Sclerosis Treated W | 2023 |
| 2023-02-23 | Teva Pharmaceuticals USA, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC | $669 | A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i | 2023 |
| 2023-02-10 | Eli Lilly and Company | DAYTON CENTER FOR NEUROLOGICAL DISORDERS | $422 | A PHASE 4 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GALCANEZUMAB VERSUS RIM | 2023 |
| 2023-02-01 | Eli Lilly and Company | DAYTON CENTER FOR NEUROLOGICAL DISORDERS | $275 | PREVENTIVE TREATMENT OF MIGRAINE: OUTCOMES FOR PATIENTS IN REAL-WORLD HEALTHCARE SYSTEMS (TRIUMPH) | 2023 |
| 2023-01-26 | Teva Pharmaceuticals USA, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC | $140 | A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i | 2023 |
| 2023-01-26 | Teva Pharmaceuticals USA, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC | $140 | A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i | 2023 |
| 2023-01-26 | Teva Pharmaceuticals USA, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC | $140 | A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i | 2023 |
| 2023-01-20 | Eli Lilly and Company | DAYTON CENTER FOR NEUROLOGICAL DISORDERS | $8,250 | A PHASE 4 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GALCANEZUMAB VERSUS RIM | 2023 |
| 2023-01-19 | Teva Pharmaceuticals USA, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC | $34 | A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i | 2023 |
| 2023-01-12 | Teva Pharmaceuticals USA, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC | $34 | A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i | 2023 |
| 2023-01-12 | Teva Pharmaceuticals USA, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC | $34 | A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i | 2023 |
| 2023-01-12 | Teva Pharmaceuticals USA, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC | $34 | A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i | 2023 |
| 2023-01-12 | Teva Pharmaceuticals USA, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC | $34 | A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i | 2023 |
| 2023-01-12 | Teva Pharmaceuticals USA, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC | $60 | A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i | 2023 |
| 2023-01-12 | Teva Pharmaceuticals USA, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC | $34 | A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i | 2023 |
| 2022-10-20 | Teva Pharmaceuticals USA, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC | $34 | A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i | 2022 |
| 2022-10-20 | Teva Pharmaceuticals USA, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC | $34 | A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i | 2022 |
| 2022-10-20 | Teva Pharmaceuticals USA, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC | $34 | A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i | 2022 |
| 2022-10-20 | Teva Pharmaceuticals USA, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC | $34 | A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i | 2022 |
| 2022-10-20 | Teva Pharmaceuticals USA, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC | $34 | A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i | 2022 |
| 2022-09-15 | Teva Pharmaceuticals USA, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC | $34 | A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i | 2022 |
| 2022-09-15 | Teva Pharmaceuticals USA, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC | $34 | A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i | 2022 |
| 2022-09-15 | Teva Pharmaceuticals USA, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC | $34 | A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i | 2022 |
| 2022-09-15 | Teva Pharmaceuticals USA, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC | $34 | A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i | 2022 |
| 2022-09-15 | Teva Pharmaceuticals USA, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC | $34 | A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i | 2022 |
| 2022-09-15 | Teva Pharmaceuticals USA, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC | $34 | A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i | 2022 |
| 2022-09-15 | Teva Pharmaceuticals USA, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC | $34 | A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i | 2022 |
| 2022-09-15 | Teva Pharmaceuticals USA, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC | $34 | A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i | 2022 |
| 2022-09-01 | Eli Lilly and Company | DAYTON CENTER FOR NEUROLOGICAL DISORDERS | $253 | A PHASE 4, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GALCANEZUMAB VERSUS | 2022 |
| 2022-06-16 | Teva Pharmaceuticals USA, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC | $60 | A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i | 2022 |
| 2022-06-16 | Teva Pharmaceuticals USA, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC | $60 | A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i | 2022 |
| 2022-06-16 | Teva Pharmaceuticals USA, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC | $331 | A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i | 2022 |
| 2022-06-16 | Teva Pharmaceuticals USA, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC | $34 | A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i | 2022 |
| 2022-06-16 | Teva Pharmaceuticals USA, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC | $60 | A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i | 2022 |
| 2022-06-16 | Teva Pharmaceuticals USA, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC | $34 | A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i | 2022 |
| 2022-06-16 | Teva Pharmaceuticals USA, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC | $331 | A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i | 2022 |
| 2022-03-14 | Novartis Pharmaceuticals Corporation | DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC | $40,379 | AN OPEN-LABEL MULTICENTER STUDY TO ASSESS RESPONSE TO COVID-19 VACCINE IN PARTICIPANTS WITH MULTIPLE SCLEROSIS TREATED W | 2022 |
| 2022-03-10 | Teva Pharmaceuticals USA, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC | $34 | A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i | 2022 |
| 2022-03-10 | Teva Pharmaceuticals USA, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC | $34 | A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i | 2022 |
| 2022-03-10 | Teva Pharmaceuticals USA, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC | $331 | A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i | 2022 |
| 2022-03-10 | Teva Pharmaceuticals USA, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC | $60 | A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i | 2022 |
| 2022-03-10 | Teva Pharmaceuticals USA, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC | $34 | A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i | 2022 |
| 2022-03-10 | Teva Pharmaceuticals USA, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC | $34 | A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i | 2022 |
| 2022-03-01 | Biogen, Inc. | Dayton Center Of Neurological Disorders | $5 | Plegridy (peginterferon 1a) Real World Effectiveness and Safety Observational Program | 2022 |
| 2022-02-23 | Eli Lilly and Company | DAYTON CENTER FOR NEUROLOGICAL DISORDERS | $7,669 | PREVENTIVE TREATMENT OF MIGRAINE: OUTCOMES FOR PATIENTS IN REAL-WORLD HEALTHCARE SYSTEMS (TRIUMPH) | 2022 |
| 2022-01-20 | Teva Pharmaceuticals USA, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC | $34 | A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i | 2022 |
| 2022-01-20 | Teva Pharmaceuticals USA, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC | $34 | A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i | 2022 |
| 2022-01-20 | Teva Pharmaceuticals USA, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC | $34 | A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i | 2022 |
| 2022-01-20 | Teva Pharmaceuticals USA, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC | $34 | A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i | 2022 |
| 2022-01-20 | Teva Pharmaceuticals USA, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC | $331 | A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i | 2022 |
| 2021-12-16 | Teva Pharmaceuticals USA, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC | $331 | A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i | 2021 |
| 2021-12-16 | Teva Pharmaceuticals USA, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC | $34 | A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i | 2021 |
| 2021-12-16 | Teva Pharmaceuticals USA, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC | $331 | A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i | 2021 |
| 2021-12-16 | Teva Pharmaceuticals USA, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC | $34 | A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i | 2021 |
| 2021-12-16 | Teva Pharmaceuticals USA, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC | $331 | A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i | 2021 |
| 2021-12-16 | Teva Pharmaceuticals USA, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC | $34 | A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i | 2021 |
| 2021-12-16 | Teva Pharmaceuticals USA, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC | $331 | A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i | 2021 |
| 2021-12-16 | Teva Pharmaceuticals USA, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC | $331 | A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i | 2021 |
| 2021-10-21 | Teva Pharmaceuticals USA, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC | $1,500 | A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i | 2021 |
| 2021-09-09 | Teva Pharmaceuticals USA, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC | $331 | A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i | 2021 |
| 2021-09-09 | Teva Pharmaceuticals USA, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC | $331 | A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i | 2021 |
| 2021-09-09 | Teva Pharmaceuticals USA, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC | $331 | A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i | 2021 |
| 2021-09-09 | Teva Pharmaceuticals USA, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC | $331 | A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i | 2021 |
| 2021-09-09 | Teva Pharmaceuticals USA, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC | $331 | A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i | 2021 |
| 2021-09-09 | Teva Pharmaceuticals USA, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC | $331 | A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i | 2021 |
| 2021-09-09 | Teva Pharmaceuticals USA, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC | $34 | A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i | 2021 |
| 2021-09-09 | Teva Pharmaceuticals USA, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC | $331 | A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i | 2021 |
| 2021-08-12 | Teva Pharmaceuticals USA, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC | $34 | A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i | 2021 |
| 2021-08-12 | Teva Pharmaceuticals USA, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC | $331 | A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i | 2021 |
| 2021-08-12 | Teva Pharmaceuticals USA, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC | $34 | A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i | 2021 |
| 2021-08-12 | Teva Pharmaceuticals USA, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC | $331 | A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i | 2021 |
| 2021-06-24 | Teva Pharmaceuticals USA, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC | $34 | A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i | 2021 |
| 2021-05-27 | Teva Pharmaceuticals USA, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC | $331 | A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i | 2021 |
| 2021-05-13 | Teva Pharmaceuticals USA, Inc. | DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC | $331 | A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i | 2021 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Centerville, OH, county Montgomery County, OH, state Ohio; placed by its city name.
| Measure | Place (city or town) Centerville, OH | County Montgomery County, OH | State Ohio |
|---|---|---|---|
| Population B01003 | 25,205 | 536,096 | 11,810,293 |
| Population, 2020 census P1 | 24,240 | 537,309 | 11,799,448 |
| Median age B01002 | 46.4 | 38.8 | 39.7 |
| Under 18 B01001 | 19.3% | 22.2% | 22.0% |
| 65 and over B01001 | 29.0% | 18.6% | 18.3% |
| Households B11001 | 11,829 | 231,319 | 4,863,191 |
| Foreign born B05002 | 6.8% | 5.3% | 5.2% |
| Median household income B19013 | $85,492 | $66,139 | $71,389 |
| Median family income B19113 | $115,308 | $87,506 | $92,749 |
| Per capita income B19301 | $50,775 | $38,450 | $40,552 |
| Poverty rate B17001 | 8.6% | 15.0% | 13.3% |
| Unemployment rate B23025 | 3.4% | 5.7% | 4.8% |
| Civilian labor force B23025 | 12,634 | 269,810 | 5,994,779 |
| Mean commute (minutes) B08013 | 20.4 | 21.9 | 23.4 |
| Bachelor's degree or higher B15003 | 47.3% | 31.3% | 31.5% |
| Housing units B25001 | 12,143 | 252,843 | 5,292,391 |
| Owner-occupied B25003 | 67.0% | 62.5% | 67.2% |
| Renters B25003 | 33.0% | 37.5% | 32.8% |
| Median home value B25077 | $287,200 | $180,900 | $214,800 |
| Median gross rent B25064 | $1,270 | $1,026 | $1,034 |
| White, not Hispanic B03002 | 81.7% | 67.7% | 75.8% |
| Black B03002 | 6.2% | 20.4% | 12.0% |
| Hispanic or Latino B03002 | 5.7% | 4.2% | 4.8% |
| Asian B03002 | 2.2% | 2.2% | 2.5% |
| American Indian and Alaska Native B03002 | 0.0% | 0.0% | 0.1% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Centerville, OH.
Comments